The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges

Bibliography

• Bittar R, Giral P, Aslangul E, Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. Antivir Ther 2012
   PubMedGoogle Scholar
• Dube MP, Parker RA, Tebas P, Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000;20:1066-71
   PubMed Web of Science ®Google Scholar
• Lo J, Grinspoon S. Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk? Curr Opin HIV AIDS 2008;3:207-13
   PubMedGoogle Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:10-14
   PubMed Web of Science ®Google Scholar
• Domingo P, Labarga P, Palacios R, Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004;18:1475-8
   PubMed Web of Science ®Google Scholar
• Grinspoon SK, Grunfeld C, Kotler DP, State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008;118:198-210
   PubMed Web of Science ®Google Scholar
• Worm SW, De WS, Weber R, Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation 2009;119:805-11
   PubMed Web of Science ®Google Scholar
• Worm SW, Friis-Moller N, Bruyand M, High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010;24:427-35
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Furrer H, Rickenbach M, Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007;45:111-19
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-12
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA, Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Hamad MA, Routh C, Connolly V. Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions. Expert Opin Pharmacother 2011;12:2673-81
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and coronary heart disease evaluation (Greace) study: a post-hoc analysis. Lancet 2010;376:1916-22
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Daskalopoulos GN, Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011;43:167-71
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-83
   PubMed Web of Science ®Google Scholar
• Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002;2:91-106
   PubMedGoogle Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39:307-12
   PubMed Web of Science ®Google Scholar
• Melroe NH, Kopaczewski J, Henry K, Huebsch J. Intervention for hyperlipidemia associated with protease inhibitors. J Assoc Nurses AIDS Care 1999;10:55-69
   PubMedGoogle Scholar
• Dube MP, Stein JH, Aberg JA, Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medical association of the Infectious Disease Society of America and the adult AIDS clinical trials group. Clin Infect Dis 2003;37:613-27
   PubMed Web of Science ®Google Scholar
• Schambelan M, Benson CA, Carr A, Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-75
   PubMed Web of Science ®Google Scholar
• Lo J. Dyslipidemia and lipid management in HIV-infected patients. Curr Opin Endocrinol Diabetes Obes 2011;18:144-7
   PubMed Web of Science ®Google Scholar
• Soler A, Deig E, Guil J, Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia. Med Clin (Barc) 2006;127:250-2
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008;6:572-8
   PubMed Web of Science ®Google Scholar
• Pham PA, la Porte CJ, Lee LS, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009;53:4385-92
   PubMed Web of Science ®Google Scholar
• Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23
   PubMed Web of Science ®Google Scholar
• Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med 2002;112:505
   PubMed Web of Science ®Google Scholar
• Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 2003;17:207-10
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94:1140-6
   PubMed Web of Science ®Google Scholar
• Bonnet F, urillac-Lavignolle V, Breilh D, Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials 2007;8:53-60
   PubMed Web of Science ®Google Scholar
• Stein JH, Merwood MA, Bellehumeur JL, Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004;147:E18
   PubMed Web of Science ®Google Scholar
• Aberg JA, Zackin RA, Brobst SW, A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS clinical trials group study 5087. AIDS Res Hum Retroviruses 2005;21:757-67
   PubMed Web of Science ®Google Scholar
• Ahmed MH. Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers. Med Hypotheses 2006;66:440-1
   PubMed Web of Science ®Google Scholar
• Aslangul E, Assoumou L, Bittar R, Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010;24:77-83
   PubMed Web of Science ®Google Scholar
• van der LM, Sankatsing R, Schippers E, Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007;12:1127-32
   PubMedGoogle Scholar
• Bottaro EG, Caravello O, Scapellato PG, Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience. Enferm Infecc Microbiol Clin 2008;26:325-9
   PubMedGoogle Scholar
• Calza L, Colangeli V, Manfredi R, Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005;19:1103-5
   PubMed Web of Science ®Google Scholar
• Singh S, Willig JH, Mugavero MJ, Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis 2011;52:387-95
   PubMed Web of Science ®Google Scholar
• Benesic A, Zilly M, Kluge F, Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004;32:229-33
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003;17:851-9
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med 2012;172:144-52
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus–a matter for debate. Nat Rev Endocrinol 2012;8:133-4
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010;11:1965-70
   PubMed Web of Science ®Google Scholar
• Wohl DA, Waters D, Simpson RJ Jr, Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008;47:1105-8
   PubMed Web of Science ®Google Scholar
• Negredo E, Molto J, Puig J, Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006;20:2159-64
   PubMed Web of Science ®Google Scholar
• Chow D, Chen H, Glesby MJ, Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS 2009;23:2133-41
   PubMed Web of Science ®Google Scholar
• Berg-Wolf MV, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS 2008;22(6):483-488
   PubMedGoogle Scholar
• Chastain LM, Bain AM, Edwards KL, A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidol 2007;1:634-9
   PubMed Web of Science ®Google Scholar
• Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis 2007;6:15
   PubMed Web of Science ®Google Scholar
• Samineni D, Fichtenbaum CJ. Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert Opin Drug Metab Toxicol 2010;6:995-1004
   PubMed Web of Science ®Google Scholar
• Badiou S, Merle De BC, Dupuy AM, Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172:273-9
   PubMed Web of Science ®Google Scholar
• Thomas JC, Lopes-Virella MF, Del Bene VE, Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy 2000;20:727-34
   PubMed Web of Science ®Google Scholar
• Rao A, D'Amico S, Balasubramanyam A, Maldonado M. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004;327:315-18
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol 2010;4:279-87
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Coraza I, Smith EO, Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab 2011;96:2236-47
   PubMed Web of Science ®Google Scholar
• Gerber JG, Kitch DW, Fichtenbaum CJ, Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008;47:459-66
   PubMed Web of Science ®Google Scholar
• Samson SL, Pownall HJ, Scott LW, Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials 2006;27:518-30
   PubMed Web of Science ®Google Scholar
• Souza SA, Chow DC, Walsh EJ, Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia. Hawaii Med J 2010;69:122-5
   PubMedGoogle Scholar
• Gerber MT, Mondy KE, Yarasheski KE, Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004;39:419-25
   PubMed Web of Science ®Google Scholar
• Dube MP, Wu JW, Aberg JA, Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS clinical trials group study A5148. Antivir Ther 2006;11:1081-9
   PubMed Web of Science ®Google Scholar
• Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis 2012;25:10-16
   PubMed Web of Science ®Google Scholar
• Arendt BM, Mohammed SS, Ma DW, Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition. Curr HIV Res 2011;9:128-35
   PubMedGoogle Scholar
• Crum-Cianflone N, Krause D, Wessman D, Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons(*). HIV Med 2011;12:463-71
   PubMedGoogle Scholar
• Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 2007;12:740-7
   PubMed Web of Science ®Google Scholar
• Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009;11:188-95
   PubMed Web of Science ®Google Scholar